AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) – Equities researchers at Jefferies Group issued their Q1 2018 earnings per share estimates for AcelRx Pharmaceuticals in a research report issued on Friday. Jefferies Group analyst M. Andrews anticipates that the specialty pharmaceutical company will post earnings of ($0.24) per share for the quarter. Jefferies Group also issued estimates for AcelRx Pharmaceuticals’ Q2 2018 earnings at ($0.29) EPS, Q3 2018 earnings at ($0.17) EPS and Q4 2018 earnings at ($0.30) EPS.
Separately, Zacks Investment Research downgraded AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, January 23rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $6.21.
Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) opened at $2.15 on Monday. The company has a debt-to-equity ratio of -0.43, a current ratio of 4.78 and a quick ratio of 4.71. AcelRx Pharmaceuticals has a 1-year low of $1.55 and a 1-year high of $5.75.
A number of hedge funds have recently modified their holdings of ACRX. Virtu Financial LLC bought a new stake in AcelRx Pharmaceuticals in the fourth quarter worth approximately $120,000. Geller Family Office Services LLC bought a new stake in shares of AcelRx Pharmaceuticals during the third quarter valued at approximately $460,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of AcelRx Pharmaceuticals during the second quarter valued at approximately $530,000. Institutional investors and hedge funds own 9.31% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/03/14/analysts-offer-predictions-for-acelrx-pharmaceuticals-incs-q1-2018-earnings-acrx.html.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.